Syndromic Multiplex Diagnostics Market Report 2025

The syndromic multiplex diagnostics market size has grown rapidly in recent years. It will grow from $3.11 billion in 2024 to $3.43 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth observed during the historic period can be attributed to the increasing demand for rapid and precise diagnostics, greater awareness of early disease detection, a rise in hospital-acquired infections, wider adoption of molecular diagnostics, higher healthcare spending, and an expanding need for point-of-care testing.

The syndromic multiplex diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.96 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth during the forecast period can be attributed to increasing investments in research and development, greater adoption in low-resource settings, expanding healthcare infrastructure in developing countries, rising government initiatives for infectious disease control, and growing demand for decentralized testing. Key trends in the forecast period include advancements in multiplex polymerase chain reaction (PCR) technologies, innovations in microfluidics and lab-on-chip systems, enhanced automation in sample processing, development of point-of-care molecular platforms, integration of cloud-based diagnostic data systems, and progress in portable diagnostic devices.

The rising prevalence of infectious diseases is anticipated to drive growth in the syndromic multiplex diagnostics market in the coming years. Infectious diseases are caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which invade the body, multiply, and cause various symptoms and health complications. The increase in infectious diseases is largely attributed to growing global travel, which facilitates the spread of pathogens across borders and populations. Syndromic multiplex diagnostics support infectious disease management by enabling the rapid and simultaneous detection of multiple pathogens from a single sample. These diagnostics enhance both the speed and accuracy of diagnosis, allowing for timely treatment decisions and improved patient outcomes. For example, in March 2023, the Centers for Disease Control and Prevention, a national public health organization in the United States, reported 8,331 cases of tuberculosis (TB) in 2022, marking a 5.9% rise from 7,874 cases in 2021. Consequently, the growing prevalence of infectious diseases is contributing to the expansion of the syndromic multiplex diagnostics market.

Leading companies in the syndromic multiplex diagnostics sector are concentrating on developing technologically advanced solutions, including AI-powered diagnostic algorithms, to improve the speed, accuracy, and breadth of pathogen detection. AI-enhanced diagnostic algorithms are sophisticated computational tools that use artificial intelligence, particularly machine learning and deep learning methods, to analyze complex clinical and laboratory data for faster and more precise disease diagnosis. For instance, in January 2024, Qiagen N.V., a molecular diagnostics company based in the Netherlands, launched two syndromic testing panels, the Gastrointestinal Panel 2 and the Meningitis and Encephalitis Panel for its QIAstat Dx platform. These panels allow rapid and accurate detection of multiple pathogens in a single test, aiding clinical decision-making and improving patient outcomes. The QIAstat-Dx system also incorporates advanced data analytics, helping healthcare professionals efficiently identify and manage infectious disease outbreaks.

In June 2022, R Biopharm AG, a biotechnology company based in Germany, acquired AusDiagnostics Pty Ltd. for an undisclosed sum. Through this acquisition, R Biopharm aims to expand its product portfolio, enter new clinical diagnostics market segments, and accelerate its international growth strategy, positioning itself as a globally recognized system supplier in laboratory diagnostics across multiple regions. AusDiagnostics Pty Ltd., headquartered in Australia, specializes in in vitro diagnostics (IVD) and syndromic multiplex diagnostics.

Major players in the syndromic multiplex diagnostics market are Roche Molecular Systems Inc., Abbott Laboratories, Becton Dickinson and Company, Hologic Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Cepheid, Bosch Healthcare Solutions GmbH, Biocartis NV, Luminex Corporation, Curetis GmbH, Accelerate Diagnostics Inc., Applied BioCode Inc., Ador Diagnostics Ltd., Akonni Biosystems Inc., Alveo Technologies Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, Nanomix Inc., Primerdesign Ltd.

North America was the largest region in the syndromic multiplex diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in syndromic multiplex diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the syndromic multiplex diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Syndromic multiplex diagnostics is a molecular testing approach that simultaneously detects and identifies multiple pathogens or biomarkers linked to a particular syndrome from a single patient sample. This approach employs multiplex polymerase chain reaction (PCR) or comparable technologies to provide rapid and comprehensive results. By identifying multiple potential causes at once, these diagnostics support timely and accurate diagnosis of infectious diseases, enhancing clinical decision-making and patient outcomes.

The primary product categories in syndromic multiplex diagnostics include instruments, reagents, software, and services. Syndromic multiplex diagnostic instruments are sophisticated molecular testing systems designed to detect multiple pathogens simultaneously from a single patient sample, using integrated platforms such as real-time polymerase chain reaction (PCR) or microfluidics for fast and precise disease diagnosis. The types of samples analyzed include blood, urine, saliva, and tissue. These diagnostics employ various technologies, including polymerase chain reaction (PCR), mass spectrometry, nucleic acid amplification tests, and next-generation sequencing, and are applied in areas such as infectious diseases, respiratory diseases, gastrointestinal diseases, sexually transmitted infections, and central nervous system diseases. Their end users include clinical laboratories, hospitals, pharmaceutical and biotechnology companies, research institutes, and other organizations.

The syndromic multiplex diagnostics market research report is one of a series of new reports that provides syndromic multiplex diagnostics market statistics, including the syndromic multiplex diagnostics industry global market size, regional shares, competitors with the syndromic multiplex diagnostics market share, detailed syndromic multiplex diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the syndromic multiplex diagnostics industry. This syndromic multiplex diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The syndromic multiplex diagnostics market consists of revenues earned by entities by providing services such as diagnostic workflow integration services, remote testing, clinical decision support tools for syndromic testing, and regulatory and compliance support for diagnostic labs. The market value includes the value of related goods sold by the service provider or included within the service offering. The syndromic multiplex diagnostics market also includes sales of multiplex diagnostic instruments, reagents and consumables, software, and accessories used for the simultaneous detection of multiple pathogens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.